Articles related to ASCO

“This is the first time we are really talking seriously about cure in one of the worst malignancies imaginable.” — Norman Sharpless, MD

“We are starting to lose our junior faculty, which means you no longer have a pipeline…they often are overworked, and they don’t see a way out of their situation.”

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

A study on palliative care for advanced lung cancer patients shows that telehealth can match in-person visits in improving quality of life and patient satisfaction. These findings support the broader implementation of telehealth in oncology.